Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 113 publications

Most recent new publication 4/2025

See all their publications

Vacancies in this group

Working in this group

Postdoctoral Training Fellow

  • Chelsea
  • Structural Biology
  • Salary Range: £45,600 - £55,000 per annum
  • Fixed term

Under the leadership of Claudio Alfieri, we are seeking to appoint a Postdoctoral Training Fellow to join the Molecular Mechanisms of Cell Cycle Regulation Group at the Chester Beatty Laboratories, Fulham Road in London. This project aims to investigate the molecular mechanisms of cell cycle regulation by macromolecular complexes involved in cell proliferation decisions, by combining genome engineering, proteomics and in situ structural biology. For general information on Post Doc's at The ICR can be found here. Key Requirements The successful candidate must have a PhD in cellular biochemistry and experience in Cryo-EM and CLEM is desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 7 years Department/Directorate Information: The candidate will work in the Molecular Mechanisms of Cell Cycle Regulation Group within the ICR Division of Structural Biology headed by Prof. Laurence Pearl and Prof. Sebastian Guettler. The division has state-of-the-art facilities for protein expression and biophysics/x-ray crystallography, in particular the Electron Microscopy Facility is equipped with a Glacios 200kV with Falcon 4i detector with Selectris energy filter and the ICR has access to Krios microscopes via eBIC and the LonCEM consortium. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Claudio Alfieri via Email on [email protected]

Data Scientist

  • Sutton
  • Cell and Molecular Biology
  • Salary Range: £39,805 to £49,023 per annum
  • Fixed term

Under the guidance of Professor Trevor Graham, we are seeking to recruit a Data Scientist to support Data Science research across the ICR. The successful candidate will particularly work on the analysis of spatial data including multiplex immunohistochemistry, H&Es and spatial transcriptomics. About you The successful candidate must have: A PhD in quantitative subject, or likely to be awarded PhD in the near future. Research experience equivalent to PhD level will be considered. Undergraduate degree, or Masters or equivalent in a quantitative subject. Skills in bioinformatics computing coding, in languages including R, Python and other scripting languages as is appropriate. Experience of using high performance computing (HPC) systems for scientific computing. Experience of computational biology research methodologies pertinent to the role. Department/Directorate Information The Data Science Committee is chaired by Professor Trevor Graham, providing academic leadership of data science at the ICR to maximise the impact of our cancer research, by applying innovative data science and computation tools (in addition to our traditional areas of strength) to tackle the important cancer questions and ensuring infrastructure is considered to enable this. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Prof Trevor Graham [email protected].

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

23/06/25

Dr Maggie Cheang, a breast cancer researcher at The Institute of Cancer Research, London, has been awarded the prestigious CL Oakley lectureship.

The lectureship, which was founded in 1979 in honour of the late Professor CL Oakley, with funds to endow it provided by the sixth European Congress of Pathology, is given out every two years to recognise original investigative research in laboratory medicine.

Dr Cheang, who is a Group Leader for Integrative Genomics Analysis in Clinical Trials within The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU), will present a lecture on Wednesday 25 June, at the Joint Ghent Pathology and Pathological Society Annual Meeting 2025. Her talk, titled “The Transformative Impact of Molecular Pathology on Breast Cancer Care: Diagnostic Advances, Therapeutic Precision, and Future Directions” will highlight both her key contributions and the cutting-edge research currently led by her team at the ICR.

Advancing the molecular understanding of breast cancer 

Dr Cheang was selected in recognition of her contributions to understanding the molecular biology of breast cancer intrinsic subtypes. She is a co-inventor of PAM50/Prosigna assay, now included in international clinical guidelines and endorsed by NICE. Her early work in classical molecular pathology including optimising the oestrogen receptor detection and defining the prognostic value of Ki67 in relation to molecular classification in breast cancer, was also acknowledged.

She currently leads a multidisciplinary research group of statistical, computational and translational scientists, strategically within the ICR-CTSU. Her team develops novel analytical approaches to interrogate high-dimensional multi-omics data from bio-specimens collected in clinical trials, focusing on identifying and developing the most effective molecular diagnostics to predict tumour response and treatment sensitivity. She also serves as biomarker and bioinformatics lead on biomarker-enriched clinical trials.

Commitment to training the next generation

Alongside her scientific leadership, Dr Cheang has mentored a number of early-career researchers, many of whom have gone on to become senior scientists and made substantial contributions in cancer genomics and translational pathology. Trainees from her lab have received awards at the San Antonio Breast Cancer Symposium for three consecutive years.

She serves on trial management and translational research committees for several phase II and III clinical trials, including ICR-CTSU trials such as POETIC, POETIC-A, PALLET, PHOENIX, and TNT.

Speaking about receiving the lectureship award, Dr Cheang said:

"I’m honoured to receive this lectureship, which recognises both the work of my team and the passion I’ve carried since my doctoral and postdoctoral training to improve the lives of people affected by breast cancer. It’s also a valuable opportunity to share our research and represent the ICR within the global scientific community."

Past recipients of CL Oakley lectureship award include Jorge Reis-Filho and Barry Gusterson. Jorge Reis-Filho became the Professor and Chair of Molecular Pathology while at the ICR. He is now the Vice President of Cancer Biomarker Development at AstraZeneca. Barry Gusterson was the Professor of Pathology and Head of Molecular Pathology at the ICR. He went on to become the founding director of the Breast Cancer Now Toby Robins Research Centre. The ICR’s Professor Trevor Graham, Director of the Centre for Evolution and Cancer, also won the award in 2016 before he joined the ICR.